论文部分内容阅读
本刊每年的例行“中国药店排行榜”统计,今年以更为全面的“中国药店发展报告”的形式与广大读者见面了。通过对2012～2013年度中国连锁药店、大店以及网上药店相关经营数据的统计分析、政策梳理、不同区域市场状况的深度采访等,以期形成本年度行业发展的年鉴。与一年来我们在采访中感受到的悲观情绪笼罩的氛围迥然不同,数据中体现出了报春花般的明媚之色,请允许我们小小地夸张一下以“逆袭”为题,以表欣喜之情,以振行业之志。2012年,中国连锁药店前100位企业销售总额实现了17.51%的增长,其中前三甲(国大药房、重庆桐君阁和广东大参林)业绩首次突破40亿元,百强门槛也首次跨过2亿元,标志中国药品零售业又进入崭新的一页。
Our annual routine “” Chinese pharmacy rankings “statistics, this year to a more comprehensive ” China pharmacy development report “in the form of the majority of readers met. Through the statistical analysis of relevant operating data of China’s chain pharmacies, big pharmacies and online pharmacies in 2012 ~ 2013, combing policies and in-depth interviews with market conditions in different regions, etc., the annual yearbook of industrial development in this year will be formed. In contrast to the atmosphere of pessimism we have felt in the interview over the past year, the figures reflect the primrose-like bright colors, allowing us to exaggerate slightly to the title of ”counterattack" Table delight, in order to vibrate industry ambition. In 2012, the total sales of the top 100 chain pharmacies in China achieved a 17.51% increase. Among them, the top three armures (Guoda Pharma, Chongqing Tongju Pavilion and Guangdong Dagarin) exceeded 4 billion yuan for the first time, Over 200 million yuan marked China’s pharmaceutical retailing industry has entered a new page.